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Lung cancer is the leading cause of cancer death world-wide.1 Current treatment modalities, including chemother-
apy, radiotherapy, and surgery, have provided only limited
improvement in the natural history of this disease. Therefore,
the development of new therapeutic strategies is highly awaited.2
In the last years, there has been an explosion in lung cancer
genetic and biologic knowledge, providing us with many
novel potential targets for the development of different mo-
lecular targeted therapies. At least two of these novel agents,
erlotinib and bevacizumab, have been proven to prolong
survival in large randomized trials and serve as a proof of the
concept for the role of this new category of drugs in the
treatment of advanced non-small cell lung cancer
(NSCLC).3,4 Nevertheless, it seems that the greatest benefit
obtained with these compounds, at least for epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), is
confined to a small patient subgroup with specific biological
features.5 The discovery of activating EGFR mutations in the
tyrosine kinase domain that increase sensitivity to EGFR-
TKIs has opened a new avenue to patient selection for
molecular targeted therapies.6 However, most smoke-related
bronchogenic neoplasms possess multiple molecular alter-
ations, and resistance to selective targeted agents can be
explained, at least in part, by the presence of alternative
pathways of cell proliferation signaling.
For this reason, two new strategies for the simultaneous
inhibition of multiple molecular targets are being pursued.
One of these entails the combination of different molecular
target inhibitors, and the other uses single small molecules
inhibiting multiple targets.
COMBINATION OF TARGET AGENTS
The diversity of molecular abnormalities in NSCLC
may partly contribute to its resistance to therapy. It is there-
fore widely accepted that one approach to improve the effi-
cacy of cancer therapy is the development of rational com-
binations of anticancer agents that may exhibit synergistic
interactions. At present, a reasonable approach is to combine
different target agents inhibiting complementary signaling
pathways. The combination of different specific molecular
target inhibitors is especially appealing because such an
approach may theoretically improve clinical efficacy with
minimal cumulative toxicity.7
This is the basis, for example, for the combination of
erlotinib and bevacizumab, which demonstrated encouraging
results in a phase I/II study of 40 patients with pretreated
non-squamous stage IIIB-IV NSCLC.8 This combination
was well tolerated; mild to moderate skin rash, proteinuria,
and diarrhea were the most common adverse events, and no
dose-limiting adverse effects were reported. No arterial
thrombo-embolic events or severe hemoptysis was observed.
Objective responses were observed in 20% of patients, and
65% had stable disease. Even more exciting was the demon-
stration of a median time to progression of 7 months and a
median survival of 12.6 months. However, the results of this
phase II trial require confirmation in large phase III studies
such as the ongoing Beta-Lung Trial (bevacizumab and
erlotinib vs erlotinib).
This combination was also studied in a phase II trial in
which 120 patients with NSCLC, previously treated with a
single line of chemotherapy, were randomized to receive
second-line chemotherapy alone (docetaxel or pemetrexed),
chemotherapy with bevacizumab, or bevacizumab with erlo-
tinib.9 Although the results are preliminary, they suggest
superior activity with regimens including bevacizumab. Ad-
verse effects seemed to be reduced in patients receiving the
biological combination without chemotherapy, which sug-
gests an overall improved therapeutic index with targeted
therapy combinations compared with the conventional che-
motherapy-based approach. Other target agent combinations,
such as EGFR-TKIs with mTOR or Ras/Raf/Erk inhibitors,
are under evaluation in NSCLC.7
MULTI-TARGET AGENTS
Agents targeting multiple pathways in tumor growth
are also highly attractive, potentially offering the benefits of
combined therapy within a single agent. Most newer agents
inhibits more than one receptor with tyrosine kinase activity.
This approach has been subject of considerable research in
lung cancer.10 In fact, compounds such as ZD6474 (van-
detinib), SU11248 (sunitinib), and BAY 43-9006 (sorafenib),
multi-TKIs, are under study in NSCLC.
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ZD6474 (VANDETINIB)
ZD6474 selectively targets two key pathways in
tumor growth by inhibiting vascular endothelial growth
factor (VEGF)-dependent tumor angiogenesis and epider-
mal growth factor (EGF)-dependent tumor cell proliferation
and survival. ZD6474 is a novel oral reversible inhibitor of
ATP binding to vascular endothelial growth factor receptor-2
(VEGFR-2) or KDR and to EGFR tyrosine kinase. RET
kinase has been identified as a third target for ZD6474.11
ZD6474 has shown excellent reversible inhibition of
tumor cell growth in a broad range of preclinical models,
including lung cancer xenografts, and it has been demon-
strated to enhance the efficacy of radiation and chemotherapy
drugs, such as paclitaxel.12,13 ZD6474 has also displayed
anti-tumor activity in a xenograft model with resistance to
EGFR inhibitors (cetuximab and gefitinib), suggesting that
this agent may be an effective treatment against tumors with
acquired or intrinsic EGFR resistance for its ability to inhibit
VEGF signaling.14
Two phase I studies that demonstrated a maximal
tolerated dose of 300 mg were conducted in the United States,
Australia, and Japan. Common adverse events were diarrhea,
rash, and asymptomatic QTc prolongation.15
Three randomized phase II trials of ZD6474 at doses of
100 or 300 mg (two in second- and one in first-line treatment)
have been performed among patients with advanced NSCLC.
To determine the additional benefit of VEGFR tyrosine ki-
nase inhibition, a comparative study of ZD6474 and gefitinib
has been initiated in 168 previously treated patients with
stage IIIB-IV NSCLC. Crossover from one agent to the other
was permitted after progression on the initially assigned
agent. ZD6474 showed a significant improvement in progres-
sion-free survival (PFS) compared with gefitinib (11.0 vs 8.1
weeks, respectively; HR 0.69, p 0.025), although overall
survival (OS) was not superior.16
In the other two trials with the same design (an open-
label safety run-in phase followed by a randomized placebo-
controlled phase), the efficacy of ZD6474 in combination
with standard chemotherapy regimens is being compared
with that of standard chemotherapy alone: one ongoing with
carboplatin-paclitaxel in first-line treatment17 and the second
completed with docetaxel in patients who progressed after
platinum-containing therapy.18 In first-line treatment, the
run-in phase of the study demonstrated that the combination
of ZD6474 and carboplatin-paclitaxel was generally well
tolerated without mutually additive toxicity.17 Partial re-
sponses were observed in 7 of 18 patients, and stable disease
of 12 weeks or longer was observed in another two patients.
These preliminary results have supported progression to the
randomized phase, which is currently ongoing. In second-line
treatment, a randomized phase II trial with 127 patients
compared docetaxel alone against the combination of do-
cetaxel with placebo or vandetanib 100 mg or 300 mg daily.18
The combination with the 100-mg dose was associated with
a strong trend toward improved PFS (12 vs 19 weeks; HR 
0.64, p  0.074) but with no difference in OS. No improve-
ments were seen when vandetanib was given at the higher
dose of 300 mg daily. There is no clear explanation for the
lack of addictive or synergistic effect at higher doses. Based
on the favorable results of this study, a prospective random-
ized phase III trial has been initiated to compare docetaxel
alone with docetaxel/vandetanib in the setting of second-line
treatment of advanced NSCLC.
These studies of a broad population of patients with
advanced NSCLC show that ZD6474 is well tolerated both as
single agent and in combination with chemotherapy, with
promising data in the treatment of recurrent disease. The
development of this agent in other NSCLC stages (EORTC
phase II trial: radiotherapy vs radiotherapy followed by
ZD6474 vs radiotherapy concomitant with ZD6474 in pa-
tients with NSCLC stage III after two cycles of platinum-
based chemotherapy as induction) and in small cell lung
cancer has been initiated.
SU11248 (SUNITINIB)
SU11248 is a novel oral multi-target TKI, with anti-
tumor and anti-angiogenic activities. Sunitinib has been
identified as a potent inhibitor of VEGFR-1, VEGFR-2,
fetal liver tyrosine kinase receptor 3 (FLT3), c-KIT (stem-
cell factor [SCF] receptor), and platelet-derived growth factor
(PDGFR)- and - in both biochemical and cellular assays.
In mouse xenograft models, SU11248 exhibits broad and
potent anti-tumor activity causing regression, growth arrest,
or substantially reduced growth of various human cell lines,
including NSCLC.19
Administered orally at 50 mg per day for 4 weeks every
6 weeks, this agent seems to be well tolerated, with the main
adverse effects represented by sore mouth, edema, asthenia,
skin toxicity, hypertension, and mild myelo-suppression.20
SU11248 is under clinical evaluation in NSCLC in second-line
treatment, both as single agent and in combination with erlo-
tinib. Tested in 63 patients with previously treated NSCLC,
sunitinib had an encouraging response rate of 9.5%, with an
additional 43% of stable disease, a median PFS of 11.3
weeks, and a median OS of 24 weeks.21 Sunitinib was
generally well tolerated; the most frequent toxicities were
grade 1 and 2 fatigue, myalgias, and stomatitis. In this trial,
there were bleeding complications in three patients, although
the relationship between the bleeding events and sunitinib
was tenuous in two of these patients. A broad phase III
program has been launched with this agent in NSCLC.
BAY 43-9006 (SORAFENIB)
BAY 43-9006 is a novel oral kinase inhibitor targeting
RAF kinase. In preclinical models, this agent has activity against
several other kinases, including VEGFR-2, PDGFR-, c-KIT,
and FLT3. Thus, it has the potential to prevent tumor growth
by combining inhibition of both tumor cell proliferation and
tumor angiogenesis. BAY 43-9006 has shown significant
dose-dependent anti-tumor activity in preclinical models of
different human tumor types, including NSCLC.22 It is well
tolerated at 400 mg twice a day; drug-related adverse events
were mainly mild-to-moderate and included hand-foot skin
reaction, diarrhea, fatigue, hypertension, pain, and rash.23
Because preclinical data in the A549 NSCLC xenograft
model show that BAY 43-9006 does not antagonize the effect
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of gefitinib, a phase I study of this combination was conducted.24
This trial showed that the recommended dose for the combi-
nation of sorafenib and gefitinib is 400 mg twice a day and
250 mg daily, respectively. This combination was well tol-
erated and demonstrated anti-tumor activity, primarily
through disease stabilization effects in 63% of patients. Sor-
afenib was also administered in a single-arm phase II trial to
52 patients as salvage therapy for advanced NSCLC. Al-
though no objective responses were seen, 59% of patients
experienced stable disease, and the median PFS and OS were
2.7 and 6.7 months, respectively.25 Modest diarrhea, hand-
foot syndrome, stomatitis, and hypertension were seen, and
there was one fatal bleeding event. A randomized phase III
trial of carboplatin and paclitaxel with or without sorafenib as
first-line treatment of NSCLC has been initiated.
CONCLUSIONS
Preliminary preclinical and clinical data suggest that
targeting multiple pathways in cancer cells might be an
effective anti-tumor treatment strategy in NSCLC. The two
approaches described are appealing because of their potential
ability to block several pathways, thereby overcoming possi-
ble resistance to one single selective targeted agent. However,
clinical experience in this field is still limited. More research
is needed to assess whether the efficacy of target agent
combinations or of multi-target drugs is superior to current
chemotherapy or biological approaches.
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